Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 92

1.

Prediagnosis biomarkers of insulin-like growth factor-1, insulin, and interleukin-6 dysregulation and multiple myeloma risk in the Multiple Myeloma Cohort Consortium.

Birmann BM, Neuhouser ML, Rosner B, Albanes D, Buring JE, Giles GG, Lan Q, Lee IM, Purdue MP, Rothman N, Severi G, Yuan JM, Anderson KC, Pollak M, Rifai N, Hartge P, Landgren O, Lessin L, Virtamo J, Wallace RB, Manson JE, Colditz GA.

Blood. 2012 Dec 13;120(25):4929-37. doi: 10.1182/blood-2012-03-417253. Epub 2012 Oct 16. Erratum in: Blood. 2014 Sep 11;124(11):1845-7.

2.

Insulin-like growth factor-1- and interleukin-6-related gene variation and risk of multiple myeloma.

Birmann BM, Tamimi RM, Giovannucci E, Rosner B, Hunter DJ, Kraft P, Mitsiades C, Anderson KC, Colditz GA.

Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):282-8. doi: 10.1158/1055-9965.EPI-08-0778.

3.

Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma: biological insights and early treatment strategies.

Landgren O.

Hematology Am Soc Hematol Educ Program. 2013;2013:478-87. doi: 10.1182/asheducation-2013.1.478. Review.

PMID:
24319222
4.

Classifying ultra-high risk smoldering myeloma.

Waxman AJ, Mick R, Garfall AL, Cohen A, Vogl DT, Stadtmauer EA, Weiss BM.

Leukemia. 2015 Mar;29(3):751-3. doi: 10.1038/leu.2014.313. Epub 2014 Nov 5. No abstract available.

PMID:
25371175
5.

Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.

Douglas JB, Silverman DT, Pollak MN, Tao Y, Soliman AS, Stolzenberg-Solomon RZ.

Cancer Epidemiol Biomarkers Prev. 2010 Sep;19(9):2298-306. doi: 10.1158/1055-9965.EPI-10-0400. Epub 2010 Aug 10.

6.

[Analysis of serum levels of selected biological parameters in monoclonal gammopathy of undetermined significance and multiple myeloma].

Scudla V, Budíková M, Petrová P, Minarík J, Pika T, Bacovský J, Adamová D, Langová K; Ceská myelomová skupina..

Klin Onkol. 2010;23(3):171-81. Czech.

PMID:
20608327
7.

[The significance of IGF-1, VEGF, IL-6 in multiple myeloma progression].

Guo YQ, Chen SL.

Zhonghua Xue Ye Xue Za Zhi. 2006 Apr;27(4):231-4. Chinese.

PMID:
16875552
8.

Agent Orange Exposure and Monoclonal Gammopathy of Undetermined Significance: An Operation Ranch Hand Veteran Cohort Study.

Landgren O, Shim YK, Michalek J, Costello R, Burton D, Ketchum N, Calvo KR, Caporaso N, Raveche E, Middleton D, Marti G, Vogt RF Jr.

JAMA Oncol. 2015 Nov;1(8):1061-8. doi: 10.1001/jamaoncol.2015.2938.

PMID:
26335650
9.

Serum insulinlike growth factor is not elevated in patients with multiple myeloma but is still a prognostic factor.

Standal T, Borset M, Lenhoff S, Wisloff F, Stordal B, Sundan A, Waage A, Seidel C.

Blood. 2002 Dec 1;100(12):3925-9. Epub 2002 Jul 18.

10.

Insulin-like growth factor pathway genes and blood concentrations, dietary protein and risk of prostate cancer in the NCI Breast and Prostate Cancer Cohort Consortium (BPC3).

Tsilidis KK, Travis RC, Appleby PN, Allen NE, Lindström S, Albanes D, Ziegler RG, McCullough ML, Siddiq A, Barricarte A, Berndt SI, Bueno-de-Mesquita HB, Chanock SJ, Crawford ED, Diver WR, Gapstur SM, Giovannucci E, Gu F, Haiman CA, Hayes RB, Hunter DJ, Johansson M, Kaaks R, Kolonel LN, Kraft P, Le Marchand L, Overvad K, Polidoro S, Riboli E, Schumacher FR, Stevens VL, Trichopoulos D, Virtamo J, Willett WC, Key TJ.

Int J Cancer. 2013 Jul 15;133(2):495-504. doi: 10.1002/ijc.28042. Epub 2013 Feb 15.

11.

Serum concentrations of Dickkopf-1 protein are increased in patients with multiple myeloma and reduced after autologous stem cell transplantation.

Politou MC, Heath DJ, Rahemtulla A, Szydlo R, Anagnostopoulos A, Dimopoulos MA, Croucher PI, Terpos E.

Int J Cancer. 2006 Oct 1;119(7):1728-31.

12.

Value of circulating insulin-like growth factor-associated proteins for the detection of stage I non-small cell lung cancer.

Kubasiak JC, Seder CW, Pithadia R, Basu S, Fhied C, Phillips WW, Daly S, Shersher DD, Yoder MA, Chmielewski G, Edell ES, Maldonado F, Liptay MJ, Borgia JA.

J Thorac Cardiovasc Surg. 2015 Mar;149(3):727-34.e1-3; discussion 734. doi: 10.1016/j.jtcvs.2014.08.085. Epub 2014 Sep 19.

13.
14.

Insulin, insulin-like growth factor-I, and risk of breast cancer in postmenopausal women.

Gunter MJ, Hoover DR, Yu H, Wassertheil-Smoller S, Rohan TE, Manson JE, Li J, Ho GY, Xue X, Anderson GL, Kaplan RC, Harris TG, Howard BV, Wylie-Rosett J, Burk RD, Strickler HD.

J Natl Cancer Inst. 2009 Jan 7;101(1):48-60. doi: 10.1093/jnci/djn415. Epub 2008 Dec 30.

15.

Circulating concentrations of insulin-like growth factor-I, insulin-like growth factor-binding protein-3, genetic polymorphisms and mammographic density in premenopausal Mexican women: results from the ESMaestras cohort.

Rinaldi S, Biessy C, Hernandez M, Lesueur F, dos-Santos-Silva I, Rice MS, Lajous M, Lopez-Ridaura R, Torres-Mejía G, Romieu I.

Int J Cancer. 2014 Mar 15;134(6):1436-44. doi: 10.1002/ijc.28469. Epub 2013 Oct 5. Erratum in: Int J Cancer. 2016 Sep 15;139(6):E10.

16.

Plasma insulin-like growth factor-I, insulin-like growth factor-binding proteins, and prostate cancer risk: a prospective study.

Stattin P, Bylund A, Rinaldi S, Biessy C, Déchaud H, Stenman UH, Egevad L, Riboli E, Hallmans G, Kaaks R.

J Natl Cancer Inst. 2000 Dec 6;92(23):1910-7.

PMID:
11106682
17.

Cytokines (IL-6, TNF-alpha, IL-1alpha) and soluble interleukin-2 receptor as serum tumor markers in multiple myeloma.

Filella X, Blade J, Guillermo AL, Molina R, Rozman C, Ballesta AM.

Cancer Detect Prev. 1996;20(1):52-6.

PMID:
8907203
18.

Immunohistochemical analysis of NOTCH1 and JAGGED1 expression in multiple myeloma and monoclonal gammopathy of undetermined significance.

Skrtić A, Korać P, Krišto DR, Ajduković Stojisavljević R, Ivanković D, Dominis M.

Hum Pathol. 2010 Dec;41(12):1702-10. doi: 10.1016/j.humpath.2010.05.002. Epub 2010 Aug 30.

PMID:
20800871
19.

Insulin-like growth factor induces the survival and proliferation of myeloma cells through an interleukin-6-independent transduction pathway.

Ferlin M, Noraz N, Hertogh C, Brochier J, Taylor N, Klein B.

Br J Haematol. 2000 Nov;111(2):626-34.

PMID:
11122111
20.

The relationship between soluble receptor of interleukin-6 with angiogenic cytokines and proliferation markers in multiple myeloma.

Tsirakis G, Pappa CA, Kaparou M, Boula A, Katsomitrou V, Xekalou A, Kyriakaki S, Alexandrakis MG.

Tumour Biol. 2013 Apr;34(2):859-64. doi: 10.1007/s13277-012-0618-6. Epub 2012 Dec 16.

PMID:
23242610

Supplemental Content

Support Center